Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats opioid-induced constipation (OIC). Sold as Symproic. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Naldemedine tosylate (sold as Symproic), first approved Mar 23, 2017, with 0 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Symproic
Part D
$10.1M
+4%
4,178
Medicaid spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Symproic
$2.2M for 4,587 prescriptions, −16% on 2024
Where Medicare prescribes it
18,887 Part D claims in 2024; each state's share of its claims against the national share; see Part D by state
Most, against the national rate
Maryland 2.9×, North Carolina 2.1×, Pennsylvania 2.1×
Least
New York 0.5×, Florida 0.6×, Texas 0.9×
What pharmacies pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
Symproic 0.2 mg tablet: $16.25 per unitBrand · +5% in a year
How its trials ended
9 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Of the 5 whose ending is known, 80% met their primary endpoint, 0% missed it and 20% stopped early.
Met its primary endpoint444%Met its primary endpointCount4Share44%
Ongoing333%OngoingCount3Share33%
Completed, result not reported111%Completed, result not reportedCount1Share11%
Stopped: enrollment or feasibility111%Stopped: enrollment or feasibilityCount1Share11%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
First approved in Japan the same month as the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Symproic, new ingredientA drug with a new active ingredient indicated for the treatment of opioid-induced constipation. · Shionogi & Co., Ltd. · Mar 30, 2017 · Review report
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA